Research & Regulatory News

The Compounded GLP-1 Crackdown

UKPWritten and published by UK Peptides2 min readUpdated 4 cited sources

The short answer

On 30 April 2026 the FDA proposed permanently excluding semaglutide, tirzepatide and liraglutide from the 503B Bulk Drug Substances List. If finalised, that closes the last legal pathway for most large-scale compounded GLP-1s. It followed 30 warning letters to telehealth companies in March 2026.

Key facts

Proposal date
30 April 2026
Compounds named
Semaglutide, tirzepatide, liraglutide
Mechanism
Removal from the 503B Bulks List
Warning letters
30 to telehealth companies, March 2026
Comment period
Closed end of June 2026
Trigger
Shortage declared over, 21 February 2025
Jurisdiction
United States, not the UK

US compounding law permits pharmacies to prepare a version of a commercially available drug in defined circumstances, one of which is a declared shortage. When demand for semaglutide and tirzepatide outran supply, that exemption opened, and a large compounding industry grew inside it, much of it distributing through telehealth platforms rather than traditional pharmacy.

What changed

The FDA declared the semaglutide shortage over on 21 February 2025, which removed the main legal basis for compounding it. Enforcement escalated through 2026: 30 warning letters went to telehealth companies in March, and on 30 April the agency proposed removing semaglutide, tirzepatide and liraglutide from the 503B Bulk Drug Substances List (the list of ingredients large outsourcing facilities are permitted to use). A comment period ran to the end of June 2026.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

The safety record behind it

The FDA had received more than 455 adverse event reports linked to compounded semaglutide and more than 320 linked to compounded tirzepatide as of early 2025. A substantial share involved dosing errors, several requiring hospitalisation, arising from patients drawing doses themselves from multi-dose vials rather than using a metered pen. That is a failure mode created by the presentation rather than by the molecule.

Why this is not a UK story, and why it matters here anyway

The 503B Bulks List is a US regulatory instrument with no UK equivalent, and the MHRA operates a different framework. But the underlying pattern is the same one the MHRA acted on when it opened investigations into UK retailers making therapeutic claims about peptides in April 2026: demand for incretin compounds outrunning licensed supply, and a grey market forming in the gap.

The distinction that matters most

Compounded GLP-1, licensed GLP-1 and research material are three different things and should never be conflated. A compounded preparation is made by a pharmacy for administration to a person. A licensed product has a marketing authorisation. Material supplied for laboratory research is neither: it is not a medicine, not a compounded preparation, not an alternative to either, and not supplied for human use. Nothing in this regulatory story creates a route from one category to another.

What happens next

Finalising the proposal could take months, and the outcome was not settled at the time of writing. If it is finalised, the practical effect is that mass compounding of these three compounds ends in the United States, leaving licensed products and clinical trials as the routes to them.

Frequently asked questions

Does this affect the UK?

Not directly. The 503B Bulks List is a US instrument. The MHRA operates a separate framework, though it has taken its own enforcement action in this area.

Why were compounded versions available at all?

US law permits compounding of a commercially available drug during a declared shortage. The semaglutide shortage was declared over in February 2025, removing that basis.

Is research material a form of compounded GLP-1?

No. Compounded preparations are made by pharmacies for administration to people. Research material is supplied for laboratory use only and is not an alternative to any medicine.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Research & Regulatory News articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.